39 related articles for article (PubMed ID: 11423629)
1. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
Kharas MG; Yusuf I; Scarfone VM; Yang VW; Segre JA; Huettner CS; Fruman DA
Blood; 2007 Jan; 109(2):747-55. PubMed ID: 16954505
[TBL] [Abstract][Full Text] [Related]
2. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
[TBL] [Abstract][Full Text] [Related]
3. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
4. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
5. Quick success for cancer kinase treatment.
Nat Med; 2001 Jun; 7(6):637. PubMed ID: 11385473
[No Abstract] [Full Text] [Related]
6. Cancer research. Why some leukemia cells resist STI-571.
Marx J
Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
[No Abstract] [Full Text] [Related]
7. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Druker BJ; Lydon NB
J Clin Invest; 2000 Jan; 105(1):3-7. PubMed ID: 10619854
[No Abstract] [Full Text] [Related]
8. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Shah NP; Sawyers CL
Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
[No Abstract] [Full Text] [Related]
9. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
10. Resistance to imatinib mesylate in chronic myeloid leukaemia.
Melo JV; Chuah C
Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]